Talaris Therapeutics, Inc. (Nasdaq: TALS) announced the closure of its initial public offering, raising approximately $150 million by selling 8,825,000 shares at $17.00 each. The shares began trading on Nasdaq on May 7, 2021. Additionally, the underwriters have a 30-day option to purchase up to 1,323,750 additional shares. The funds will support Talaris's development of innovative cell therapies aimed at improving the standard of care in solid organ transplantation and treating severe autoimmune diseases.
Talaris Therapeutics announced its initial public offering (IPO) pricing of 8,825,000 shares at $17.00 per share, expected to generate approximately $150 million before expenses. The shares will trade on Nasdaq under the ticker symbol “TALS” starting May 7, 2021, with the offering closing on May 11, 2021, pending customary conditions. An additional 1,323,750 shares may be purchased by underwriters within 30 days. This IPO aims to support Talaris's development of innovative therapies for organ transplantation and severe autoimmune diseases.